Jiangsu Aoyang Technology Ltd

Aoyang Health released its 2026 interim report, with net profit attributable to the parent company of 24.16 million yuan, down 23.42% from the same period last year. Total operating revenue was 823 million yuan, down 8.89% year-on-year. Net cash flow from operating activities was negative 49.77 million yuan, marking a second consecutive year of improvement. The latest asset-liability ratio was 89.84%, gross margin was 12.04%, return on equity was 12.08%, and diluted earnings per share was 0.03 yuan.

Aoyang Group, a shareholder holding more than 5% of Aoyang Health, released the pledge on 10 million shares on July 8, accounting for 12.16% of its holdings and 1.31% of the company's total share capital. At the same time, it pledged 10 million shares, also representing 12.16% of its holdings and 1.31% of total share capital. As of the announcement date, Aoyang Group has cumulatively pledged 80 million shares, which is 97.32% of its holdings. In the first quarter of 2026, Aoyang Health achieved revenue of 407 million yuan and a net profit attributable to the parent company of 5.24 million yuan.